GlassScriptPhysician profile
Joe D Riddle
NPI 1336121573
$4,297.44
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $745 · 2021: $1,463 · 2022: $802 · 2023: $58.02 · 2024: $13.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $71.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $71.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $513.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $416.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.49 | 2019-2022 | |
| Novo Nordisk INC | $326.00 | 2019-2022 | |
| Abbvie INC. | $269.24 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $249.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $220.41 | 2019-2022 | |
| Amgen INC. | $212.61 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $195.70 | 2019-2023 | |
| Pfizer INC. | $176.82 | 2019-2022 | |
| Amarin Pharma, INC. | $176.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $170.60 | 2019-2021 | |
| Astellas Pharma US INC | $154.01 | 2019-2022 | |
| Eisai INC. | $110.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.53 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $66.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.71 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $55.02 | 2020-2021 | |
| Biogen, INC. | $51.99 | 2021 | |
| Sunovion Pharmaceuticals INC. | $50.09 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $38.70 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $36.42 | 2021-2022 | |
| Almatica Pharma LLC | $27.80 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $18.63 | 2019 | |
| Xeris Pharmaceuticals, INC. | $17.80 | 2022 | |
| Genentech USA, INC. | $14.85 | 2020 | |
| Ibsa Pharma INC. | $14.78 | 2020 | |
| Inogen, INC. | $14.12 | 2022 | |
| Dexcom, INC. | $13.75 | 2022 | |
| Medtronic USA, INC. | $13.24 | 2019 | |
| Paratek Pharmaceuticals, INC. | $12.77 | 2021 | |
| Qol Medical, LLC | $12.34 | 2019 | |
| Allergan, INC. | $12.22 | 2020 | |
| Bardy Diagnostics, INC. | $10.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Riddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.